Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

24
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
24
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

33
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
33
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

42
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
42
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. 冠動脈バイパス手術 (newton- Cabg Cardiolink-5) の後のサフェノス静脈移植の通路性に対するエヴォロキュマブの効果: 国際的,ランダム化,ダブルブラインド,プラセボ対照試験

冠動脈バイパス手術 (NEWTON- CABG CardioLink-5) の後のサフェノス静脈移植の通路性に対するエヴォロキュマブの効果: 国際的,ランダム化,ダブルブラインド,プラセボ対照試験

Subodh Verma1, Lawrence A Leiter2, Hwee Teoh3

  • 1Division of Cardiac Surgery, St Michael's Hospital-Unity Health Toronto, Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; North York Diagnostic and Cardiac Centre, Toronto, ON, Canada.

Lancet (London, England)
|September 4, 2025

関連する実験動画

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
08:05

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

4.3K
Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg
09:04

Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg

Published on: November 19, 2019

8.8K
Vein Interposition Model: A Suitable Model to Study Bypass Graft Patency
07:22

Vein Interposition Model: A Suitable Model to Study Bypass Graft Patency

Published on: January 15, 2017

8.9K

PubMed で要約を見る

まとめ
この要約は機械生成です。

冠動脈バイパス手術後のエヴォロキュマブによる集中的なLDL- C低下は,静脈移植疾患を減少させなかった. 早期のLDL-C減少は,早期のSVG不全を引き起こすメカニズムに影響を与えないようです.

関連する実験動画

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
08:05

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

4.3K
Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg
09:04

Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg

Published on: November 19, 2019

8.8K
Vein Interposition Model: A Suitable Model to Study Bypass Graft Patency
07:22

Vein Interposition Model: A Suitable Model to Study Bypass Graft Patency

Published on: January 15, 2017

8.9K

科学分野:

  • 心血管医学
  • 薬理学について
  • 外科 革新

背景:

  • 静脈移植 (Saphenous vein graft,SVG) の不全は,冠動脈バイパス移植 (CABG) の後の重大な合併症である.
  • SVG不全における低密度脂質タンパク質コレステロール (LDL-C) の正確な役割については,さらなる解明が必要である.
  • 早期にLDL-Cを低下させる薬剤を投与することで,治療戦略が提供される可能性があります.

研究 の 目的:

  • エボロキュマブによる早期の,集中的なLDL-C低下が,SVG疾患の進行を予防する効果を評価する.
  • 静脈移植手術を受けた患者の24ヶ月の静脈移植疾患 (VGDR) へのエヴォロキュマブの影響を調査する.

主な方法:

  • NEWTON- CABG CardioLink-5試験は,多センター,ダブルブラインド,ランダム化,プラセボ対照試験でした.
  • スタチンの治療で,少なくとも2つのSVGでCABGを受けた成人は,エヴォロキュマブまたはプラセボを2週間ごとに皮下投与した.
  • 主なエンドポイントは,血管図による≥50%のSVG閉塞と定義された24ヶ月のVGDRでした.

主要な成果:

  • エボロキュマブは24ヶ月で平均48. 4%のプラセボ調整によるLDL- Cの減少を達成しました.
  • 24ヶ月のVGDRは,エヴォロキュマブ群では21. 7%であり,プラセボ群では19. 7%であった (差は2. 0%,p=0. 44).
  • エヴォロキュマブとプラセボ群の有害事象のプロファイルは似ていた.

結論:

  • エボロキュマブを早期に投与すると,CABGの24ヶ月後にSVGの病気が有意に減少しなかった.
  • エボロキュマブによるLDL- Cの大幅な低下は,早期のSVG不全につながる病理的プロセスを変化させなかった.
  • SVG病の予防のための代替メカニズムや治療目標を探るには,さらなる研究が必要になる可能性があります.